NHS England have recently proposed that NICE should take a more direct role in determining which pro...
Read moreThis study determines if EU pricing and reimbursement bodies have revised their pricing and reimburs...
Read moreEuropean payers have not considered biosimilars to be comparable to their reference products or full...
Read moreA recent publication from the WHO identifies that EU pharmaceutical drug prices are too high and tha...
Read morePharmaceutical companies are able to charge significantly higher prices as these products are addres...
Read moreNew legislation has enabled AIFA to approve reimbursement for Avastin for off-label usage in the tre...
Read moreThis issue includes topics such as the recent AIFA approval of Avastin for off label use in Wet-AMD ...
Read moreA recent Biosimilar pricing announcement of 72% discount of an anti-tumour necrosis factor blows con...
Read moreRecent initiatives indicate EU member states are heading for potential centralised drug procurement
Read moreRemap Consulting presents NICE's highly specialised technology methodology to EUCOPE
Read more